Hologic (NASDAQ:HOLX) Rating Lowered to “Hold” at Argus

Argus cut shares of Hologic (NASDAQ:HOLX) from a buy rating to a hold rating in a report published on Monday morning, Marketbeat reports.

HOLX has been the subject of a number of other reports. Raymond James restated an “outperform” rating and issued a $90.00 price objective (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Royal Bank of Canada lowered their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a report on Thursday, February 6th. Mizuho lowered their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. Finally, Morgan Stanley dropped their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $84.62.

Hologic Price Performance

HOLX stock opened at $62.08 on Monday. The stock has a market cap of $13.93 billion, a PE ratio of 19.58, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic has a one year low of $61.70 and a one year high of $84.67. The firm has a 50 day simple moving average of $68.77 and a two-hundred day simple moving average of $75.64.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, analysts predict that Hologic will post 4.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Hologic

Several institutional investors and hedge funds have recently modified their holdings of HOLX. Swedbank AB lifted its position in shares of Hologic by 18.8% in the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after purchasing an additional 306,562 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in shares of Hologic by 55.1% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 7,449 shares of the medical equipment provider’s stock worth $607,000 after purchasing an additional 2,645 shares during the period. Stephens Inc. AR lifted its position in shares of Hologic by 50.8% in the 3rd quarter. Stephens Inc. AR now owns 6,445 shares of the medical equipment provider’s stock worth $525,000 after purchasing an additional 2,172 shares during the period. Farther Finance Advisors LLC lifted its position in shares of Hologic by 27.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical equipment provider’s stock worth $164,000 after purchasing an additional 434 shares during the period. Finally, Van ECK Associates Corp purchased a new stake in shares of Hologic in the 3rd quarter worth about $725,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.